Literature DB >> 26077627

Ophthalmic use of blood-derived products.

Ryan B Nugent1, Graham A Lee2.   

Abstract

There is a wide spectrum of blood-derived products that have been used in many different medical and surgical specialties with success. Blood-derived products for clinical use can be extracted from autologous or allogeneic specimens of blood, but recombinant products are also commonly used. A number of blood derivatives have been used for a wide range of ocular conditions, from the ocular surface to the retina. With stringent preparation guidelines, the potential risk of transmission of blood-borne diseases is minimized. We review blood-derived products and how they are improving the management of ocular disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  albumin; cryoprecipitate; fibrin glue; fibronectin; fresh frozen plasma; ophthalmology; plasmin; platelet rich plasma; serum; whole blood

Mesh:

Substances:

Year:  2015        PMID: 26077627     DOI: 10.1016/j.survophthal.2015.03.003

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  11 in total

1.  Surgical treatment of macular holes with and without the use of autologous platelet-rich plasma.

Authors:  Alexander A Shpak; Dmitry O Shkvorchenko; Eugenia A Krupina
Journal:  Int Ophthalmol       Date:  2021-01-03       Impact factor: 2.031

Review 2.  Solid Platelet Rich Plasma in Corneal Surgery.

Authors:  Francisco Arnalich; Alejandra E Rodriguez; Alvaro Luque-Rio; Jorge L Alio
Journal:  Ophthalmol Ther       Date:  2016-05-14

Review 3.  Safety of Cultivated Limbal Epithelial Stem Cell Transplantation for Human Corneal Regeneration.

Authors:  J Behaegel; S Ní Dhubhghaill; C Koppen; N Zakaria
Journal:  Stem Cells Int       Date:  2017-03-30       Impact factor: 5.443

4.  Differential profile of protein expression on human keratocytes treated with autologous serum and plasma rich in growth factors (PRGF).

Authors:  Eduardo Anitua; María de la Fuente; Francisco Muruzabal; Ronald Mauricio Sánchez-Ávila; Jesús Merayo-Lloves; Mikel Azkargorta; Felix Elortza; Gorka Orive
Journal:  PLoS One       Date:  2018-10-12       Impact factor: 3.240

5.  Quantification of Growth Factors and Fibronectin in Diverse Preparations of Platelet-Rich Plasma for the Treatment of Ocular Surface Disorders (E-PRP).

Authors:  Alejandra E Rodriguez; Sandra Gisbert; Antonio Palazón; Jorge L Alio
Journal:  Transl Vis Sci Technol       Date:  2020-05-21       Impact factor: 3.283

6.  The Effect of Plasma Rich in Growth Factors on Microglial Migration, Macroglial Gliosis and Proliferation, and Neuronal Survival.

Authors:  Noelia Ruzafa; Xandra Pereiro; Alex Fonollosa; Javier Araiz; Arantxa Acera; Elena Vecino
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

7.  Cord blood and amniotic membrane extract eye drop preparations display immune-suppressive and regenerative properties.

Authors:  Dinara Samarkanova; Steven Cox; Diana Hernandez; Luciano Rodriguez; Maria Luisa Pérez; Alejandro Madrigal; Anna Vilarrodona; Sergio Querol; Ricardo P Casaroli-Marano
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

8.  The corneal epitheliotrophic abilities of lyophilized powder form human platelet lysates.

Authors:  Lily Wei Chen; Chien-Jung Huang; Wen-Hui Tu; Chia-Ju Lu; Yi-Chen Sun; Szu-Yuan Lin; Wei-Li Chen
Journal:  PLoS One       Date:  2018-03-16       Impact factor: 3.240

9.  Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine.

Authors:  Dinara Samarkanova; Steven Cox; Diana Hernandez; Luciano Rodriguez; Ricardo P Casaroli-Marano; Alejandro Madrigal; Sergio Querol
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

10.  Characteristics of Platelet Lysate Compared to Autologous and Allogeneic Serum Eye Drops.

Authors:  Jie Zhang; Daryl Crimmins; James M Faed; Peter Flanagan; Charles N J McGhee; Dipika V Patel
Journal:  Transl Vis Sci Technol       Date:  2020-03-24       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.